Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemigatinib

FDA-approved product (tablet, oral), marketed as Pemazyre.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pemigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cholangiocarcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pemigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma

    NCT07780838 · start 2026-11-01

    Registered record
    Registry ID
    NCT07780838
    Conditions
    Locally Advanced Ampulla of Vater Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Extrahepatic Cholangiocarcinoma; Locally Advanced Gallbladder Carcinoma; Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Ampulla of Vater Carcinoma; Metastatic Biliary Tract Carcinoma; Metastatic Extrahepatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Ampulla of Vater Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Ampulla of Vater Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Ampulla of Vater Carcinoma; Unresectable Biliary Tract Carcinoma; Unresectable Extrahepatic Cholangiocarcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
    Interventions
    Biospecimen Collection; Cisplatin; Computed Tomography; Durvalumab; Gemcitabine; Magnetic Resonance Imaging; Pemigatinib; Survey Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-11-01
    Completion
    2027-12-31
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Ampulla of Vater Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Extrahepatic Cholangiocarcinoma; Locally Advanced Gallbladder Carcinoma +19 more
    InterventionBiospecimen Collection; Cisplatin; Computed Tomography; Durvalumab +4 more
    PhasePhase 2
    Registry statusRecruiting

  • Molecularly Tailored Therapy in Advanced Pancreatic Cancer

    NCT07802418 · start 2026-10

    Registered record
    Registry ID
    NCT07802418
    Conditions
    Pancreatic Cancer
    Interventions
    Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2032-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionArm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

    NCT07786766 · start 2026-08-20

    Registered record
    Registry ID
    NCT07786766
    Conditions
    Biliary Tract Cancer (BTC)
    Interventions
    Pemigatinb; PD-1 inhibitors; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-20
    Completion
    2028-12-31
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer (BTC)
    InterventionPemigatinb; PD-1 inhibitors; Chemotherapy
    PhasePhase 2
    Registry statusRecruiting

  • PH 2 Pemigatinib in SDH-deficient GIST

    NCT07434843 · start 2026-05-19

    Registered record
    Registry ID
    NCT07434843
    Conditions
    SDH Gene Mutation; Gastrointestinal Stromal Tumor
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-19
    Completion
    2029-04-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSDH Gene Mutation; Gastrointestinal Stromal Tumor
    InterventionPemigatinib
    PhasePhase 2
    Registry statusRecruiting

  • A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

    NCT06728410 · start 2026-01-27

    Registered record
    Registry ID
    NCT06728410
    Conditions
    Intrahepatic Cholangiocarcinoma; FGFR2 Gene Rearrangement; FGFR2 Gene Mutation
    Interventions
    Pemigatinib; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-27
    Completion
    2028-07
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntrahepatic Cholangiocarcinoma; FGFR2 Gene Rearrangement; FGFR2 Gene Mutation
    InterventionPemigatinib; Durvalumab
    PhasePhase 2
    Registry statusRecruiting

  • Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

    NCT06300528 · start 2025-10-03

    Registered record
    Registry ID
    NCT06300528
    Conditions
    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-10-03
    Completion
    2027-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory B-cell Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma
    InterventionPemigatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

    NCT06906562 · start 2025-08-26

    Registered record
    Registry ID
    NCT06906562
    Conditions
    Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
    Interventions
    Pemigatinib; Computed Tomography (CT); Magnetic Resonance Imaging; Optical Coherence Tomography; Bone Scan; Ophthalmoscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-26
    Completion
    2028-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8 +1 more
    InterventionPemigatinib; Computed Tomography (CT); Magnetic Resonance Imaging; Optical Coherence Tomography +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

    NCT06653777 · start 2025-03-27

    Registered record
    Registry ID
    NCT06653777
    Conditions
    Solid Tumor, Miscellaneous
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-27
    Completion
    2028-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Miscellaneous
    InterventionPemigatinib
    PhasePhase 2
    Registry statusRecruiting

  • Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

    NCT06439485 · start 2024-11-19

    Registered record
    Registry ID
    NCT06439485
    Conditions
    Advanced Cholangiocarcinoma; FGFR2 Fusion
    Interventions
    Pemigatinib; Atezolizumab; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-11-19
    Completion
    2030-02-22
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cholangiocarcinoma; FGFR2 Fusion
    InterventionPemigatinib; Atezolizumab; Bevacizumab
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

    NCT06551896 · start 2024-08-15

    Registered record
    Registry ID
    NCT06551896
    Conditions
    Urothelial Carcinoma; Breast Neoplasms; Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma; Other Carcinoma
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-08-15
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Breast Neoplasms; Lung Cancer; Gastric Cancer +2 more
    InterventionPemigatinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

    NCT06530823 · start 2024-08-01

    Registered record
    Registry ID
    NCT06530823
    Conditions
    Biliary Tract Carcinoma; Cholangiocarcinoma
    Interventions
    Pemigatinib and Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-08-01
    Completion
    2028-08-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Carcinoma; Cholangiocarcinoma
    InterventionPemigatinib and Durvalumab
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

    NCT06389799 · start 2024-06-20

    Registered record
    Registry ID
    NCT06389799
    Conditions
    Dedifferentiated Liposarcoma
    Interventions
    Pemigatinib; Retifanlimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-20
    Completion
    2028-12-31
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDedifferentiated Liposarcoma
    InterventionPemigatinib; Retifanlimab
    PhasePhase 2
    Registry statusRecruiting

  • Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

    NCT06302621 · start 2024-04-17

    Registered record
    Registry ID
    NCT06302621
    Conditions
    Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
    Interventions
    Afatinib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-04-17
    Completion
    2027-12-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
    InterventionAfatinib; Pemigatinib
    PhasePhase 1
    Registry statusRecruiting

  • A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

    NCT05997459 · start 2023-08-25

    Registered record
    Registry ID
    NCT05997459
    Conditions
    Locally Advanced Unresectable Gastric Cancer
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-08-25
    Completion
    2025-03-30
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Unresectable Gastric Cancer
    InterventionPemigatinib
    PhasePhase 2
    Registry statusUnknown

  • Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

    NCT05913661 · start 2023-07

    Registered record
    Registry ID
    NCT05913661
    Conditions
    Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment
    Interventions
    Pemigatinib; PD-1 Inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-07
    Completion
    2024-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor +1 more
    InterventionPemigatinib; PD-1 Inhibitors
    PhasePhase 2
    Registry statusUnknown